Norinchukin Bank The grew its holdings in Illumina, Inc. (NASDAQ:ILMN) by 6.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,131 shares of the life sciences company’s stock after acquiring an additional 625 shares during the quarter. Norinchukin Bank The’s holdings in Illumina were worth $1,758,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Paradigm Asset Management Co. LLC boosted its holdings in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after acquiring an additional 50 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in Illumina by 1.4% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after acquiring an additional 43 shares in the last quarter. State of Tennessee Treasury Department boosted its holdings in Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock worth $16,697,000 after acquiring an additional 7,040 shares in the last quarter. Bank of Nova Scotia boosted its holdings in Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock worth $14,710,000 after acquiring an additional 62,612 shares in the last quarter. Finally, Aberdeen Asset Management PLC UK boosted its holdings in Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock worth $4,775,000 after acquiring an additional 2,158 shares in the last quarter. 93.34% of the stock is owned by institutional investors and hedge funds.

In other news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $178.21, for a total value of $3,564,200.00. Following the completion of the sale, the director now directly owns 534,176 shares of the company’s stock, valued at approximately $95,195,504.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Omead Ostadan sold 1,672 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $172.73, for a total value of $288,804.56. Following the completion of the sale, the executive vice president now directly owns 26,242 shares of the company’s stock, valued at $4,532,780.66. The disclosure for this sale can be found here. Insiders sold a total of 195,434 shares of company stock valued at $37,480,647 over the last three months. Insiders own 1.60% of the company’s stock.

Shares of Illumina, Inc. (ILMN) opened at 210.72 on Friday. The stock has a market capitalization of $30.77 billion, a PE ratio of 42.28 and a beta of 0.81. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $214.04. The stock has a 50 day moving average price of $197.88 and a 200-day moving average price of $180.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.68 by $0.14. The business had revenue of $662.00 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $0.86 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current fiscal year.

WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/09/16/illumina-inc-ilmn-holdings-raised-by-norinchukin-bank-the.html.

Several equities research analysts have weighed in on the company. Barclays PLC reissued an “equal weight” rating and issued a $150.00 price target on shares of Illumina in a report on Wednesday, August 9th. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $209.78 price target for the company in a report on Wednesday, August 9th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Cowen and Company reaffirmed an “outperform” rating and set a $200.00 target price on shares of Illumina in a report on Wednesday, August 2nd. Finally, Argus lifted their target price on Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. Illumina has a consensus rating of “Hold” and an average price target of $181.76.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.